Evidence map›Paper›PMID 41760872›Full record

ArticleScientific reports2026

A comprehensive nationwide registry study of noncommunicable disease comorbidities and death in cancer patients in Norway-the NCDNOR project.

Simon Lergenmuller, Trude Eid Robsahm, Yngvar Nilssen, Knut Eirik Dalene, Wenche Nystad, Haakon E Meyer, Hein Stigum, Vidar Hjellvik, Lars J Kjerpeseth, Inger Ariansen and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Simon LergenmullerDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, P.O Box 5313, Majorstuen, 0304, Oslo, Norway. simon.lergenmuller@fhi.no.ORCID http://orcid.org/0000-0002-7976-3881
Trude Eid RobsahmDepartment of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, P.O Box 5313, Majorstuen, 0304, Oslo, Norway.ORCID http://orcid.org/0000-0002-1652-7734
Yngvar NilssenDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, P.O Box 5313, Majorstuen, 0304, Oslo, Norway.ORCID http://orcid.org/0000-0002-3620-1555
Knut Eirik DaleneDepartment of Chronic Diseases, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.ORCID http://orcid.org/0000-0002-4401-301X
Wenche NystadDepartment of Chronic Diseases, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.ORCID http://orcid.org/0000-0001-9061-6869
Haakon E MeyerDepartment of Physical Health and Ageing, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.ORCID http://orcid.org/0000-0002-3262-8260
Hein StigumDepartment of Community Medicine and Global Health, University of Oslo, P.O. Box 1130, Blindern, 0318, Oslo, Norway.ORCID http://orcid.org/0000-0002-2098-1059
Vidar HjellvikDepartment of Chronic Diseases, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.
Lars J KjerpesethDepartment of Chronic Diseases, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.ORCID http://orcid.org/0000-0002-2033-736X
Inger AriansenDepartment of Chronic Diseases, Norwegian Institute of Public Health, P.O Box 222, Skøyen, 0213, Oslo, Norway.ORCID http://orcid.org/0000-0001-8529-4826
Inger Kristin LarsenDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, P.O Box 5313, Majorstuen, 0304, Oslo, Norway.ORCID http://orcid.org/0000-0002-9601-5324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noncommunicable disease (NCD) comorbidities are common in cancer patients due to shared risk factors, but few studies have mapped their occurrence across cancer types using detailed national data. In this nationwide cohort study, we used data from Norwegian mandatory health registries to comprehensively describe NCD comorbidities at and after cancer diagnosis of 19 cancers. We included 269,956 adults registered with a first cancer in the Cancer Registry of Norway 2009-2019. Comorbidities included second cancers, cardiovascular diseases (CVDs), chronic obstructive pulmonary disease, diabetes and mental health disorders (MDs). We used intersection diagrams to examine NCD comorbidity patterns at first cancer diagnosis, and multi-state models to estimate five-year post-cancer probabilities of NCD comorbidities and death. We also provide a publicly available online application [ https://ncdapp.onrender.com/ ] with additional results and details. Comorbidity prevalence at cancer diagnosis ranged from 35% (skin cancer) to 83% (lung cancer). CVD was most prevalent, usually co-occurring with MDs or diabetes. Lowest prevalences were found for younger patients and women. Conditioning on surviving five years, comorbidity probability exceeded 50% in all sites. Our findings show substantial comorbidity burden in cancer patients, varying by cancer site, age, and sex. Knowledge of these patterns could improve NCD prevention, treatment and surveillance.

Indexed as

NeoplasmsNoncommunicable DiseasesAdultAgedAged, 80 and overCardiovascular DiseasesCohort StudiesComorbidityDiabetes MellitusFemaleHumansMaleMiddle AgedNorwayPrevalenceRegistriesCancer comorbiditiesCohort studyComorbidity patternsMulti-state modelsNational registriesNoncommunicable diseases

Identifiers

PMID41760872
PMCPMC13049054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.